bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales
bioAffinity Technologies announced that sales of its CyPath® Lung test for lung cancer increased more than 100% through the third quarter of 2026.
Story updates
01:19:29 PM UTC
SquawkNews
bioAffinity Technologies said CyPath Lung test sales rose more than 100% through Q3 2026 vs. 2025, with 1,620 tests delivered vs. 775 and ordering physicians up 89% YoY in Q3.Material DetailsContext by AI AnalystThis update reinforces early commercial traction for CyPath Lung with expanding physici…